Energesis Pharmaceuticals is developing therapeutics for diabetes, obesity, and lipid disorders by targeting brown adipose tissue (BAT). The Company’s approach is a novel strategy leveraging recent scientific insights in BAT biology to increase the body’s ability to burn stored fat and lower insulin resistance. Diabetes and its major underlying cause, obesity, have reached epidemic proportions in the U.S. and the rest of the industrialized world. However, there are presently very few safe and effective non-invasive treatments for obesity available, and new approaches for diabetes are needed. Our technology is the first to enable the development of drugs that increase energy expenditure, a strategy for addressing both obesity and diabetes that is strongly supported by the scientific literature. The Energesis management team brings a strong entrepreneurial record together with world-class scientific, medical, and product development expertise and will leverage the Company’s discovery platform to develop a new generation of agents to effectively treat metabolic disease.